Misplaced Pages

Vildagliptin/metformin, sold under the brand name Eucreas among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes. It was approved for use in the European Union in November 2007, and the approval was updated in 2008. It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin.

The most common side effects include nausea (feeling sick), vomiting, diarrhea, abdominal (tummy) pain and loss of appetite.

Medical uses

Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus:

• it is indicated in the treatment of adults who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
• it is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.
• it is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

References

1. "Eucreas 50 mg/850 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 10 May 2018. Retrieved 8 June 2020.
2. "Eucreas 50 mg/1000 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 8 June 2020.
3. Halimi S, Schweizer A, Minic B, Foley J, Dejager S (2008). "Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet". Vascular Health and Risk Management. 4 (3): 481–92. doi:10.2147/vhrm.s2503. PMC 2515409. PMID 18827867.
4. ^ "Eucreas EPAR". European Medicines Agency (EMA). Retrieved 8 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
5. "EU approves Novartis's Eucreas diabetes drug". Reuters. 25 February 2008.
6. ^ "Icandra EPAR". European Medicines Agency (EMA). Retrieved 8 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
7. ^ "Zomarist EPAR". European Medicines Agency (EMA). Retrieved 8 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
8. "Galvumet".

External links

• "Vildagliptin". Drug Information Portal. U.S. National Library of Medicine.
• "Metformin". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

• Adamantanes
• Biguanides
• Carboxamides
• Combination diabetes drugs
• Dipeptidyl peptidase-4 inhibitors
• Drugs with unknown mechanisms of action
• Guanidines
• Nitriles
• Drugs developed by Novartis
• Pyrrolidines
• Tertiary alcohols